This is a preview of subscription content, log in via an institution to check access.
Literatur
Wu YL et al (2020) Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 383(18):1711–1723
Wakelee H et al (2021) IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. https://doi.org/10.1200/JCO.2021.39.15_suppl.8500
Felip E et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398(10308):1344–1357
Spicer J et al (2021) Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J Clin Oncol. https://doi.org/10.1200/JCO.2021.39.15_suppl.8503
Gray JE et al (2020) Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol 15(2):288–293
Le Pechoux C et al (2022) Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol 23(1):104–114
Rights and permissions
About this article
Cite this article
Lungenkrebs – wir haben noch einen weiten Weg zu gehen. best practice onkologie 17, 106–111 (2022). https://doi.org/10.1007/s11654-022-00377-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11654-022-00377-5